

MIDAZOLAM

PRESENTATION:

Ampoules containing 10mg in 2ml of midazolam (5mg/ml)
Ampoules containing 10mg in 5ml of midazolam (2mg/ml)
Ampoules containing 50mg in 10ml of midazolam (5mg/ml)

Prefilled syringe containing 50mg in 50mL of midazolam (1mg/ml)

INDICATION:

Sedation
Treatment of status epilepticus

DOSE AND ADMINISTRATION:

ICU STANDARD INFUSION

Single strength

Preparation available	Amount to be diluted with glucose 5%	Final volume	Final concentration
10mg in 2ml	60mg (12ml)	60ml	1mg/ml
10mg in 5ml	60mg (30ml)	60ml	1mg/ml
50mg in 10ml	50mg(10ml)	50ml	1mg/ml
50mg in 50ml PFS	No dilution required		

Double strength

Preparation available	Amount to be diluted with glucose 5%	Final Volume	Final concentration
10mg in 2ml	120mg (24ml)	60ml	2mg/ml
10mg in 5ml	120mg (60ml)	60ml	2mg/ml
50mg in 10ml	100mg(20ml)	50ml	2mg/ml
50mg in 50ml PFS	Not suitable		

note when using preparations with a final volume of 50ml these will not be compatible with the drug library (DERS)

Sedation: Initially 2-5mg/hour titrated to the required level.

Status epilepticus: Maintenance infusion 0.05-0.4mg/kg/hr. i.e. for 70kg patient 3.5- 28mg/hr.
Use double strength midazolam.

Bolus doses

Sedation bolus doses of 500micrograms to 2 mg may be given. Bolus doses are generally given via the infusion pump. If the patient is not prescribed a continuous infusion prepare as below:

Preparation available	Amount to be diluted with glucose 5%	Final Volume	Final concentration
10mg in 2ml	10mg (2ml)	10ml	1mg/ml
10mg in 5ml	10mg (5ml)	10ml	1mg/ml
50mg in 10ml	10mg(2ml)	10ml	1mg/ml

Using the 10mg/2ml or 10mg/5ml preparation for bolus doses is preferred to prevent wastage but the 50mg/10ml preparation may be used if there are supply issues with the 10mg/2ml or 10mg/5ml preparation.

CONCENTRATION: **Single strength** :1mg/ml
Double strength:2mg/ml

STABILITY: Physically and chemically stable for 24 hours at room temperature.
Also stable in sodium chloride 0.9%.
Prefilled syringe should not be mixed with any other medicinal products

References:

1. Summary of Product Characteristics, Midazolam 5mg/ml solution for injection/infusion, .Hameln pharmaceuticals Ltd, www.medicines.org.uk/emc/product/6420/smpc last reviewed 30/04/20.
2. Injectable Medicines Guide accessed online at www.injguide.nhs.uk on 01/05/20.
3. NHS Lothian Critical Care Guideline of Treatment of status epilepticus, reviewed July 2019.
4. Summary of Product Characteristics, Midazolam injection BP 2mg/ml solution for injection or infusion, Accord Healthcare Limited. www.medicines.org.uk/emc/product/4116/smpc last reviewed 01/05/20.
5. Summary of Product Characteristics, Midazolam 1mg/ml solution for injection/infusion in a prefilled syringe, Ranbaxy UK, <https://www.medicines.org.uk/emc/product/10967/smpc> last reviewed 21/05/20

Title: Midazolam	
ID:	Authors: F Clarke
Category:	Document Version: 3
Status Draft/Final: final	Review Date: May 2022
Authoriser: Lothian Critical Care QIT Editorial Group	Authorisation Date: May 2020
Date added to Intranet June 2020	Written: May 2020
Key Words	
Comments	

